Psilocybin to promote synaptogenesis in the brains of patients with mild cognitive impairment
Medical Hypotheses April 5, 2023 Jianmeng Song, Yasaman Kambari, Aron Amaev et al. 2 citations
No Summary
Vincenzo de Luca
3 papers in the library · 3 citations · publishing 2023-2025
Papers
118. Does Psilocybin Change Synaptic Vesicular Density in the Brains of Patients With Mild Cognitive Impairment?
Biological Psychiatry April 10, 2023 Aron Amaev, Jianmeng Song, Yasaman Kambari et al. 1 citation
No Summary
Adverse event reporting and management in psilocybin therapy clinical trials: A systematic review to guide clinical and research protocol development
Progress in Neuro-Psychopharmacology and Biological Psychiatry October 23, 2025 Danielle Bukovsky, Aron Amaev, Jianmeng Song et al.
A systematic review of 42 clinical studies involving 1,068 participants found that psilocybin, when administered in controlled settings, has a favorable safety profile. Common adverse events included headache, transient increases in blood pressure, and nausea, which typically resolved on their own. Serious adverse events were reported infrequently, in only 2 of the 42 studies, and were limited to participants with underlying depressive disorders, such as suicidal behavior or hospitalization. All studies had a high risk of bias due to concerns regarding blinding. The review provides an outline of common and uncommon adverse events, serious adverse events, and considerations for future protocols.